Search

Your search keyword '"Bagué, Silvia"' showing total 8 results
Start Over Author "Bagué, Silvia" Publisher wiley
8 results on '"Bagué, Silvia"'

2. CINSARC in high‐risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG‐STS 1001 study

Author

Frezza, Anna Maria, primary, Stacchiotti, Silvia, additional, Chibon, Frederic, additional, Coindre, Jean‐Michelle, additional, Italiano, Antoine, additional, Romagnosa, Cleofe, additional, Bagué, Silvia, additional, Dei Tos, Angelo Paolo, additional, Braglia, Luca, additional, Palmerini, Emanuela, additional, Quagliuolo, Vittorio, additional, Broto, Javier Martin, additional, Lopez Pousa, Antonio, additional, Grignani, Giovanni, additional, Brunello, Antonella, additional, Blay, Jean‐Yves, additional, Beveridge, Robert Diaz, additional, Lugowska, Iwona, additional, Lesluyes, Tom, additional, Maestro, Roberta, additional, Merlo, Franco Domenico, additional, Casali, Paolo Giovanni, additional, and Gronchi, Alessandro, additional

Published
2022
Full Text
View/download PDF

3. Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: A Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial

Author

Pasquali, Sandro, primary, Palmerini, Emanuela, additional, Quagliuolo, Vittorio, additional, Martin‐Broto, Javier, additional, Lopez‐Pousa, Antonio, additional, Grignani, Giovanni, additional, Brunello, Antonella, additional, Blay, Jean‐Yves, additional, Tendero, Oscar, additional, Diaz‐Beveridge, Robert, additional, Ferraresi, Virginia, additional, Lugowska, Iwona, additional, Infante, Gabriele, additional, Braglia, Luca, additional, Merlo, Domenico Franco, additional, Fontana, Valeria, additional, Marchesi, Emanuela, additional, Donati, Davide Maria, additional, Palassini, Elena, additional, Bianchi, Giuseppe, additional, Marrari, Andrea, additional, Morosi, Carlo, additional, Stacchiotti, Silvia, additional, Bagué, Silvia, additional, Coindre, Jean Michel, additional, Dei Tos, Angelo Paolo, additional, Picci, Piero, additional, Bruzzi, Paolo, additional, Miceli, Rosalba, additional, Casali, Paolo Giovanni, additional, Gronchi, Alessandro, additional, Dani, Carla, additional, Villa, Chiara, additional, Messina, Antonella, additional, Rusi, Lorella, additional, Nuzzo, Anna Maria, additional, Nuzzo, Carmen, additional, De Paoli, Antonino, additional, Buonadonna, Angela, additional, Comandone, Alessandro, additional, Boglione, Antonella, additional, Livi, Lorenzo, additional, Greto, Daniela, additional, Riva, Nada, additional, Monti, Manuela, additional, Pennacchioli, Elisabetta, additional, De Pas, Tommaso, additional, Ippolito, Vincenzo, additional, Ledesma, Patrico, additional, Redondo, Andres, additional, Valverde, Claudia, additional, Bratos, Raquel, additional, Cruz, Josefina, additional, Martinez Trufero, Javier, additional, Cubedo, Ricardo, additional, Sevilla, Isabel, additional, Luna, Pablo, additional, Lopez, Rafael, additional, Sancho, Pilar, additional, Bally, Olivia, additional, Brahmi, Mehdi, additional, Ray‐Coquard, Isabelle, additional, Cassier, Philippe, additional, Marques, Nathalie, additional, Tassy, Luis, additional, Boudou‐Rouquette, Pascaline, additional, Tlemsani, Camille, additional, Alexandre, Jerome, additional, Goldwasser, Francois, additional, Bompas, Emmanuelle, additional, Rolland, Frederic, additional, Perrin, Christophe, additional, Talarmin, Marie, additional, Italiano, Antoine, additional, Toulmonde, Maud, additional, Laramas, Mathieu, additional, Bay, Jacques‐Olivier, additional, Dubray‐Longeras, Pascale, additional, and Rutkowski, Piotr, additional

Published
2021
Full Text
View/download PDF

4. A DNA damage repair gene‐associated signature predicts responses of patients with advanced soft‐tissue sarcoma to treatment with trabectedin

Author

Moura, David S., primary, Peña‐Chilet, Maria, additional, Cordero Varela, Juan Antonio, additional, Alvarez‐Alegret, Ramiro, additional, Agra‐Pujol, Carolina, additional, Izquierdo, Francisco, additional, Ramos, Rafael, additional, Ortega‐Medina, Luis, additional, Martin‐Davila, Francisco, additional, Castilla‐Ramirez, Carolina, additional, Hernandez‐Leon, Carmen Nieves, additional, Romagosa, Cleofe, additional, Vaz Salgado, Maria Angeles, additional, Lavernia, Javier, additional, Bagué, Silvia, additional, Mayodormo‐Aranda, Empar, additional, Vicioso, Luis, additional, Hernández Barceló, Jose Emilio, additional, Rubio‐Casadevall, Jordi, additional, de Juan, Ana, additional, Fiaño‐Valverde, Maria Concepcion, additional, Hindi, Nadia, additional, Lopez‐Alvarez, Maria, additional, Lacerenza, Serena, additional, Dopazo, Joaquin, additional, Gutierrez, Antonio, additional, Alvarez, Rosa, additional, Valverde, Claudia, additional, Martinez‐Trufero, Javier, additional, and Martín‐Broto, Javier, additional

Published
2021
Full Text
View/download PDF

6. BRAFV600E andKRASG12S mutations in peripheral nerve sheath tumours

Author

Serrano, César, primary, Simonetti, Sara, additional, Hernández-Losa, Javier, additional, Valverde, Claudia, additional, Carrato, Cristina, additional, Bagué, Silvia, additional, Orellana, Ruth, additional, Somoza, Rosa, additional, Moliné, Teresa, additional, Carles, Joan, additional, Huguet, Pere, additional, Romagosa, Cleofé, additional, and Ramón y Cajal, Santiago, additional

Published
2012
Full Text
View/download PDF

8. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.

Author

Pasquali S, Palmerini E, Quagliuolo V, Martin-Broto J, Lopez-Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz-Beveridge R, Ferraresi V, Lugowska I, Infante G, Braglia L, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Bianchi G, Marrari A, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Miceli R, Casali PG, and Gronchi A

Subjects
Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chemotherapy, Adjuvant, Humans, Ifosfamide, Neoadjuvant Therapy, Risk Assessment, Sarcoma pathology, Soft Tissue Neoplasms
Abstract

Background: The value of neoadjuvant chemotherapy in soft tissue sarcoma (STS) is not completely understood. This study investigated the benefit of neoadjuvant chemotherapy according to prognostic stratification based on the Sarculator nomogram for STS., Methods: This study analyzed data from ISG-STS 1001, a randomized study that tested 3 cycles of neoadjuvant anthracycline plus ifosfamide (AI) or histology-tailored (HT) chemotherapy in adult patients with STS. The 10-year predicted overall survival (pr-OS) was estimated with the Sarculator and was stratified into higher (10-year pr-OS < 60%) and lower risk subgroups (10-year pr-OS ≥ 60%)., Results: The median pr-OS was 0.63 (interquartile range [IQR], 0.51-0.72) for the entire study population, 0.62 (IQR, 0.51-0.70) for the AI arm, and 0.64 (IQR, 0.51-0.73) for the HT arm. Three- and 5-year overall survival (OS) were 0.86 (95% confidence interval [CI], 0.82-0.93) and 0.81 (95% CI, 0.71-0.86) in lower risk patients and 0.69 (95% CI, 0.70-0.85) and 0.59 (95% CI, 0.51-0.72) in the higher risk patients (log-rank test, P = .004). In higher risk patients, the 3- and 5-year Sarculator-predicted and study-observed OS rates were 0.68 and 0.58, respectively, and 0.85 and 0.66, respectively, in the AI arm (P = .04); the corresponding figures in the HT arm were 0.69 and 0.60, respectively, and 0.69 and 0.55, respectively (P > .99). In lower risk patients, the 3- and 5-year Sarculator-predicted and study-observed OS rates were 0.85 and 0.80, respectively, and 0.89 and 0.82, respectively, in the AI arm (P = .507); the corresponding figures in the HT arm were 0.87 and 0.81, respectively, and 0.86 and 0.74, respectively (P = .105)., Conclusions: High-risk patients treated with AI performed better than predicted, and this adds to the evidence for the efficacy of neoadjuvant AI in STS., Lay Summary: People affected by soft tissue sarcomas of the extremities and trunk wall are at some risk of developing metastasis after surgery. Preoperative or postoperative chemotherapy has been tested in clinical trials to reduce the chances of distant metastasis. However, study findings have not been conclusive. This study stratified the risk of metastasis for people affected by sarcomas who were included in a clinical trial testing neoadjuvant chemotherapy. Exploiting the prognostic nomogram Sarculator, it found a benefit for chemotherapy when the predicted risk, based on patient and tumor characteristics, was high., (© 2021 American Cancer Society.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results